|
1.
|
Hatcher H, Planalp R, Cho J, Torti FM and
Torti SV: Curcumin: from ancient medicine to current clinical
trials. Review. Cell Mol Life Sci. 65:1631–1652. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Golombick T and Diamond TH: The potential
role of curcumin (diferuloylmethane) in plasma cell
dyscrasias/paraproteinemia. Biologics. 2:161–163. 2008.PubMed/NCBI
|
|
3.
|
Golombick T, Diamond TH, Badmaev V,
Manoharan A and Ramakrishna R: The potential role of curcumin in
patients with monoclonal gammopathy of undefined significance – its
effect on paraproteinemia and the urinary N-telopeptide of type I
collagen bone turnover marker. Clin Cancer Res. 15:5917–5922.
2009.
|
|
4.
|
Kyle RA: Monoclonal gammopathy of
undetermined significance. Review. Blood Rev. 8:135–141. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Rosiñol L, Cibeira MT, Montoto S, Rozman
M, Esteve J, Filella X and Bladé J: Monoclonal gammopathy of
undetermined significance: predictors of malignant transformation
and recognition of an evolving type characterized by a progressive
increase in M protein size. Mayo Clin Proc. 82:428–434. 2007.
|
|
6.
|
Kyle RA, Therneau TM, Rajkumar SV, Larson
DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA and Melton LJ
III: Prevalence of monoclonal gammopathy of undetermined
significance. N Engl J Med. 354:1362–1369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kyle RA, Rajkumar SV, Therneau TM, Larson
DR, Plevak MF and Melton LJ III: Prognostic factors and predictors
of outcome of immunoglobulin M monoclonal gammopathy of
undetermined significance. Clin Lymphoma. 5:257–260. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Gregersen H, Ibsen J, Mellemkjoer L,
Dahlerup J, Olsen J and Sørensen HT: Mortality and causes of death
in patients with monoclonal gammopathy of undetermined
significance. Br J Haematol. 112:353–357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF,
Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen
GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and
Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive
agent, in patients with high-risk or pre-malignant lesions.
Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
|
|
10.
|
Sharma RA, Euden SA, Platton SL, Cooke DN,
Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer
SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial
of oral curcumin: biomarkers of systemic activity and compliance.
Clin Cancer Res. 10:6847–6854. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Rajkumar SV: Prevention of progression in
monoclonal gammopathy of undetermined significance. Clin Cancer
Res. 15:5606–5608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Holt PR, Katz S and Kirshoff R: Curcumin
therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci.
50:2191–2193. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Conteas CN, Panossian AM, Tran TT and
Singh HM: Treatment of HIV-associated diarrhea with curcumin. Dig
Dis Sci. 54:2188–2191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ammon HP and Wahl MA: Pharmacology of
Curcuma longa. Planta Med. 57:1–7. 1991.
|
|
15.
|
Lacombe C, Aucouturier P and Preud’homme
JL: Selective IgG1 deficiency. Clin Immunol Immunopathol.
84:194–201. 1997. View Article : Google Scholar
|
|
16.
|
Bierwirth J, Ulbricht KU, Schmidt RE and
Witte T: Association of common variable immunodeficiency with
vitamin B6 deficiency. Eur J Clin Nutr. 62:332–335. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Van der Steen P, van de Kerkhof P, der
Kinderen D, van Vlijmen I and Happle R: Clinical and
immunohistochemical responses of plantar warts to topical
immunotherapy with diphenylcyclopropenone. J Dermatol. 18:330–333.
1991.PubMed/NCBI
|
|
18.
|
Lynn J, Knight AK, Kamoun M and Levinson
AI: A 55-year-old man with hypogammaglobulinemia, lymphopenia and
unrelenting cutaneous warts. J Allergy Clin Immunol. 114:409–414.
2004.PubMed/NCBI
|
|
19.
|
Varalakshmi CH, Ali AM, Pardhasaradhi BV,
Srivastava RM, Singh S and Khar A: Immunomodulatory effects of
curcumin: in vivo. Int Immunopharmacol. 8:688–700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Gill MA, Palucka AK, Barton T, Ghaffar F,
Jafri H, Banchereau J and Ramilo O: Mobilization of plasmacytoid
and myeloid dendritic cells to mucosal sites in children with
respiratory syncytial virus and other viral respiratory infections.
J Infect Dis. 191:1105–1115. 2005. View
Article : Google Scholar
|
|
21.
|
Bayry J, Lacroix-Desmazes S, Kazatchkine
MD, Galicier L, Lepelletier Y, Webster D, Lévy Y, Eibl MM,
Oksenhendler E, Hermine O and Kaveri SV: Common variable
immunodeficiency is associated with defective functions of
dendritic cells. Blood. 104:2441–2443. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Scott-Taylor TH, Green MR, Raeiszadeh M,
Workman S and Webster AD: Defective maturation of dendritic cells
in common variable immunodeficiency. Clin Exp Immunol. 145:420–427.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Cunningham-Rundles C and Radigan L:
Deficient IL-12 and dendritic cell function in common variable
immune deficiency. Clin Immunol. 115:147–153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ravanbakhsh M, Sarafnejad A, Aghamohammadi
A, Kardar GA, Asgarian Omran H, Atarod L, Rezaei N, Shahrestani T,
Hosseini M and Moin M: CD40 ligand expression on stimulated
T-helper lymphocytes in patients with common variable
immunodeficiency. Iran J Allergy Asthma Immunol. 6:129–135.
2007.PubMed/NCBI
|
|
25.
|
Yong PF, Workman S, Wahid F, Exley A,
Webster AD and Ibrahim MA: Selective deficits in blood dendritic
cell subsets in common variable immunodeficiency and X-linked
agammaglobulinaemia but not specific polysaccharide antibody
deficiency. Clin Immunol. 127:34–42. 2008. View Article : Google Scholar
|
|
26.
|
Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ,
Moon DO, Lee CM, Ahn SC, Park YC and Park YM: Curcumin inhibits
immunostimulatory function of dendritic cells: MAPKs and
translocation of NF-kappa B as potential targets. J Immunol.
174:8116–8124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shirley SA, Montpetit AJ, Lockey RF and
Mohapatra SS: Curcumin prevents human dendritic cell response to
immune stimulants. Biochem Biophys Res Commun. 374:431–436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Martín-Ayuso M, Almeida J, Pérez-Andrés M,
Cuello R, Galende J, González-Fraile MI, Martín-Nuñez G, Ortega F,
Rodríguez MJ, San Miguel JF and Orfao A: Peripheral blood dendritic
cell subsets from patients with monoclonal gammopathies show an
abnormal distribution and are functionally impaired. Oncologist.
13:82–92. 2008.PubMed/NCBI
|
|
29.
|
McMaster ML, Kristinsson SY, Turesson I,
Björkholm M and Landgren O: Novel aspects pertaining to the
relationship of Waldenström’s macroglobulinemia, IgM monoclonal
gammopathy of undetermined significance, polyclonal gammopathy and
hypoglobulinemia. Clin Lymphoma Myeloma. 9:19–22. 2009.PubMed/NCBI
|
|
30.
|
Gregersen H, Mellemkjaer L, Ibsen JS,
Dahlerup JF, Thomassen L and Sørensen HT: The impact of M-component
type and immunoglobulin concentration on the risk of malignant
transformation in patients with monoclonal gammopathy of
undetermined significance. Haematologica. 86:1172–1179. 2001.
|
|
31.
|
Lee SW, Nah SS, Byon JS, Ko HJ, Park SH,
Lee SJ, Shin WY and Jin DK: Transient complete atrioventricular
block associated with curcumin intake. Int J Cardiol. Nov
3–2009.(Epub ahead of print).
|
